Latest Immunity Pharma News & Updates

See the latest news and media coverage for Immunity Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Immunity Pharma

Drug development company for neurodegenerative diseases

immunitypharma.com

Latest news about Immunity Pharma

Company announcements

  • Immunity Pharma

    Immunity Pharma presents new data supporting IPL344 efficacy in ALS

    Phase 2a trial results published in Muscle and Nerve show 58-64% slower ALSFRS-R progression, 27% NfL reduction, and improved survival versus controls. IPL344 was safe and well-tolerated.

  • Immunity Pharma

    Immunity Pharma announces positive Phase 2a IPL344 results in ALS

    Treatment was well tolerated with 48% slower ALSFRS-R decline. Benefits suggested in weight gain, respiration, survival. NfL reduction observed.

  • Immunity Pharma

    Immunity Pharma reports NfL reduction in IPL344-treated ALS patients

    Phase 2a study shows mean 20% plasma NfL reduction in six participants. Data presented at ALS/MND symposium. Strengthens IPL344 therapy potential.

  • Immunity Pharma

    Immunity Pharma announces promising interim IPL344 ALS trial results

    Disease progression slowed 50% in functional and respiratory endpoints. Favorable safety profile shown. Biomarker confirms Akt pathway activation.

Unlock all announcements with a

Media coverage

Unlock all articles with a

Never miss news about Immunity Pharma

Track Immunity Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.